H istorically, insurance coverage for mental health and substance abuse (MH/SA) services has been more restrictive than that for general medical conditions. 1 These more restricted benefits such as service or spending limits and higher cost-sharing have been criticized for their inflexibility in covering care needed for the sickest patients. 2, 3 This also conflicts with the principal role of insurance to insure against large financial losses resulting from illness.
Parity typically mandates insurance coverage for psychiatric disorders to be equal to that for general medical conditions. Despite considerable legislative activity toward parity, full parity has often been elusive. The 1998 federal Mental Health Parity Act (MHPA) prevented group health plans from placing lower annual or lifetime dollar limits on mental health benefits compared with medical or surgical benefits 4 and covered all psychiatric diagnoses described in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 5 However, group health plans could impose some mental health benefit restrictions that differed from medical or surgical benefits such as limits on the number of covered visits or different cost-sharing arrangements. 4, 6 Additionally, many states have enacted parity legislation for private insurance plans. These state laws differ in whether substance abuse is included in the legislation or if other exemptions apply. 7 Most states in fact have not legislated full parity. Even when states enact strong parity statutes, they do not apply to a large proportion of workers covered by self-ensured employers who are exempt under the federal Employee Retirement Income Security Act (ERISA).
Concerns about parity focus on increases in insurance costs. However, managed mental healthcare organizations, particularly behavioral health carveouts, have changed the way mental health services and costs are controlled 8 and have been widespread since the 1990s. 9 Under managed behavioral health care, evidence has accrued that parity does not have to cause major cost increases. 10 -14 It therefore became increasingly evident that benefit limits may not be necessary for containing costs under managed behavioral healthcare arrangements. 3, 15, 16 The use of managed behavioral healthcare organizations, however, creates concerns that patients may not receive needed care. 14 Still unclear in this policy debate is the net effect on quality between the opposing forces of parity (which leads to an expansion of insurance benefits) and managed care (which uses various mechanisms to restrain benefits). 17 Parity may improve quality by expanding access to needed treatments, but not if managed care organizations are too severe in their rationing of health care through the use of stringent prior authorization procedures, aggressive limiting of provider panels, or risk sharing for providers.
In June 1999, President Clinton directed the Office of Personnel Management (OPM) to implement parity in the Federal Employees' Health Benefits Program, (FEHBP) thereby expanding MH/SA coverage in the program. The FEHBP, with approximately 8.5 million enrollees, is the largest U.S. employer-based insurance program. FEHBP plans are not subject to ERISA exemptions or state parity laws. Additionally, the FEHBP parity is full parity and therefore more comprehensive than many state parity laws.
In this article, part of the first national evaluation of comprehensive parity, we examine the association between parity implementation and changes in the major depressive disorder (MDD) treatment quality for enrollees in 6 geographically diverse FEHBP plans.
MDD was chosen as a tracer condition for several reasons. It is prevalent 18 and associated with considerable functional impairment, 18 -20 including lost work productivity [21] [22] [23] and death. 24 Also, although the value of MDD treatment has improved in the 1990s, 25 it continues to be an undertreated illness. 18, 26 
MATERIALS AND METHODS
The study used deidentified information of insurance enrollees and was approved by the Harvard Medical School Institutional Review Board.
The Federal Employees' Health Benefits Program's Parity Policy
Effective January 1, 2001, the OPM required all participating plans to have MH/SA coverage that is "identical with regard to traditional medical care deductibles, coinsurance, copays and day and visit limitations" to coverage for physical health services. 27 Parity applied for all DSM-IV diagnoses but only to in-network benefits. Plans could keep cost-sharing levels and benefit limits the same as those used in 2000 for services delivered by out-of-network providers. The OPM encouraged plans to use managed care techniques to control any increases in MH/SA service utilization and expenditures. Some plans had already contracted with managed behavioral healthcare organizations to control MH/SA costs before parity was adopted; the OPM encouraged the remaining plans to do so after parity. In the 6 plans studied here, before parity implementation, benefits included 40% cost sharing and 100-day annual limits for inpatient services, and $25 cost sharing and 25 visit annual limits for outpatient services. Postparity, there was no inpatient cost sharing or annual inpatient or outpatient day/visit limits. Furthermore, outpatient cost sharing decreased to $15 per visit. All plans implemented the benefit changes on January 1, 2001. 28
Study Population
We studied adult, enrollees (ages 18 -64) who were enrolled at least 10 of 12 months for each of 4 calendar years (1999 -2003) in 6 FEHBP health plans; all of the plans included in the analysis were PPO/POS plans. One was located in the western portion of the United States (PPO-W), 2 in the northeast (PPO-NE1 and PPO-NE2), 2 in the mid-Atlantic (PPO-MA1 and PPO-MA2), and 1 in the south (PPO-S). The 6 plans were selected on the basis of geographic location, breadth of parity in state law, size of enrollee population, and interest in collaborating on the evaluation. Together, they included over 365,000 enrollees. Four plans had already contracted with managed behavioral health organizations before parity implementation. After parity, 1 of the remaining 2 (PPO-W) contracted with a managed behavioral health organization; the other (PPO-MA2) did not.
Data Sources
From each plan, we obtained 4 years of archival enrollment data, medical and behavioral health claims/encounter data, and pharmacy claims, including data for 2 years before and after parity implementation.
Establishing the Major Depressive Disorder Cohort
To enable a more nuanced understanding of MDD treatment quality, we examined indicators of receiving quality care within a calendar year as well as within an episode of acute-phase outpatient treatment. Although published guidelines recommend acute-and continuation-phase treatment of MDD, 29 -31 we focused on the acute phase because it typically is the period of most intensive treatment needs. Guideline recommendations during this phase are clear in determining minimum intensity/frequency and duration of treatments that can be applied to claims data analyses. The acute phase is considered to be the duration of time needed to resolve a patient's depressive symptoms. In efficacy trials, this period is often estimated to be 3 months. Because we cannot determine an individual patient's clinical recovery in claims data and that usual care there might be less efficient (as a result of delays in appointment scheduling, missed appointments, and so on), we defined the acute-phase period as lasting 120 days (ie, 4 months).
We applied a diagnostic algorithm to establish the depression cohort. The cohort included those with a diagnosis of MDD (International Classification of Diseases, 9th Revi-sion ͓ICD-9͔ code 296.2 or 296.3) on claims for at least 2 separate service dates (to confirm the diagnosis). If the MDD diagnosis was based on an outpatient claim, then the diagnosis must be either primary or secondary; if inpatient, we required a primary diagnosis of MDD so as to reflect the reason for hospitalization. To balance maximizing the truepositive while minimizing the false-negative rates and to include persons with MDD who are perhaps more difficult to engage in treatment, we also included persons having only 1 MDD diagnosis as long as it was either the primary diagnosis of hospitalization or it represented at least 50% of the outpatient MH/SA claims for an individual. Because this is a study examining changes in treatment quality for persons with MDD as their primary psychiatric diagnosis, we excluded enrollees who received any diagnosis of schizophrenia or bipolar disorder during the 4 years.
We included only persons who received an MDD diagnosis (rather than all depressive disorders). We did so because face validity would suggest that persons receiving a diagnosis of MDD, the most severe of the depressive disorders, are more likely to be correctly identified in administrative data. Moreover, there are no guidelines for treating other, less severe depression-spectrum disorders.
Establishing Annual Treatment and Acute-Phase Episode Cohorts
In the calendar year analyses, persons were included in the MDD cohort each calendar year they met the previously mentioned cohort criteria algorithm. Thus, persons who were in any stage of MDD treatment (ie, acute, continuation, or maintenance) were included in the analysis for that year. In the acute-phase episode analyses, we examined only treatments received for persons specifically in an acute phase of MDD outpatient treatment. Therefore, we required a period of at least 3 months without MH/SA claims before initiation of a new MDD treatment episode in the outpatient setting to ensure that treatments received represented a new episode of outpatient care. After that period, 2 MDD diagnoses on different service dates were required to begin an MDD acute phase. An acute phase also was considered to have started if the first observed MH/SA visit was coded as a depressive disorder diagnosis (ICD-9 codes 296.2, 296.3, 300.4, 301.12, 309.1, and 311) and followed by a first MDD diagnosis within 30 days of the initiating the depressive MH/SA treatment. In both scenarios, the MDD episode was considered to have begun with the first depressive diagnosis observed (eg, MDD specifically or one of the other depressive diagnoses mentioned previously). An acute-phase outpatient episode was also initiated the day after discharge from hospitalizations in which MDD was the primary diagnosis.
An outpatient acute-phase episode was considered to have ended if one of the following occurred: 1) 90 days of no outpatient MH/SA visit or no days supplied of mental health medications, 2) 120 days (ie, 4 months) after acute-phase treatment started, or 3) an inpatient MH/SA hospitalization. Subsequent outpatient MDD visits after hospitalization were considered to be a new outpatient acute-phase episode.
We considered only those acute-phase episodes that ended before and those that started after parity implementa-tion. We did not include acute-phase episodes that began before and continue after parity implementation, and we did not include episodes in which we could not observe the first 4 months of treatment before December 31, 2002.
Dependent Variables: Quality Indicators
We calculated quality measures from guidelines published by the American Psychiatric Association and the Agency for Healthcare Research and Quality. 29 -31 The guidelines specify that the use of antidepressants or psychotherapy (or both) should be based on clinical circumstances (eg, depression severity, co-occurring conditions, or complicated psychosocial situations). This level of clinical detail is not knowable in claims data; therefore, we constructed our measures considering either treatment modality. We considered 9 quality measures pertaining to MH/SA follow up in general as well as psychotherapy and pharmacotherapy specifically.
In the calendar year analyses, we examined the likelihood that MDD-diagnosed enrollees received any antidepressants, at least 1 psychotherapy visit, or either. Receiving either would be considered appropriate MDD treatment according to the guidelines (albeit a minimum quality standard). However, recognizing that different treatment modalities may be under different constraints, we also measured changes in receiving psychotherapy separately from receiving antidepressants.
In the acute-phase episode analyses, we measured frequency/intensity and/or duration of guideline-recommended treatment modalities. Specifically, the likelihood of: 1) duration of mental health follow up (visits and/or medications) Ն4 months; 2) intensity of follow-up visits, defined as within the first 2 months Ն2 visits per month and in the second 2 months Ն1 per month; 3) psychotherapy duration (Ն3 months) and intensity (Ն2 sessions per month); and 4) total days of antidepressant supplied Ն3 months. The AHRQ and APA guidelines recommend acute-phase psychotherapy occurring weekly for 12 or 16 weeks, respectively. Also, AHRQ guidelines specify that acute-phase antidepressant treatment last at least 3 months, follow-up visits to monitor medication occur at least every 2 weeks, and therapy occur weekly. 31 Thus, our quality indicators are consistent with guidelines but represent conservative measures of quality. These measures are more conservative so as to allow for potential inefficiencies that can occur in usual care (eg, missed appointments, and so on). They are also consistent with other studies in the literature that use claims data to measure depression quality of care. [32] [33] [34] [35] 
Analytic Models
Multiple logistic regression models estimated the association between the postparity period and receipt of the quality measures. For each quality measure, separate models for each health plan were fitted as a result of concerns that pooling the data would obscure plan-to-plan differences. However, some plans did not have 80% power to detect a 10 percentage point difference at a significance level of 0.05%. Therefore, we also pooled the data and conducted analyses that used plan fixed-effects models to control for plan-level differences in quality. Because the results of the pooled and unpooled analyses are similar, we report on the pooled analyses in the tables. When the results differ by individual health plan, we report those results in the text.
We conducted sensitivity analyses in which the one plan that did not contract with a managed behavioral health carveout after parity (PPO-MA2) was dropped from the analysis. Dropping PPO-MA2 did not lead to any significant changes in the results.
The primary explanatory variable of interest was a dichotomous variable indicating whether treatment occurred after the parity policy was implemented. Other explanatory variables that served as controls in each model included gender, age (as a quadratic variable), relation to insured (eg, employee versus spouse/dependent), the presence of an MDD hospitalization, the presence of a co-occurring (non-tobacco) substance use disorder, and other psychiatric co-occurring diagnoses that might signify a more complicated course (eg, anxiety, psychotic, personality, eating, adjustment, and attention deficit hyperactivity disorders). Because of the low prevalence of detected co-occurring substance use disorder in this sample, we were unable to control for it in the acutephase episode analyses.
We constructed a 95% confidence interval for the adjusted odds ratios and used a generalized estimating equations (GEE) approach to account for the multiple observations on each individual for both the annual treatment and acute-phase episode analyses. 36 
RESULTS
Across time, the change in the MDD calendar year detection rate did not change significantly from a clinical or policy perspective (Table 1) . Table 2 describes the pre-and postparity population characteristics across plans. The calendar year cohort was nearly 70% female, had a mean age of Ͻ50, and approximately 60% were employees. Co-occurring substance use disorder (SUD) diagnosis was not prevalent (Ͻ2%), but co-occurring (non-SUD) mental health diagnoses were (nearly 70%). Few received more intensive services such as inpatient, partial hospital, or residential services (1.5%). Table 3 describes the proportion of persons with MDD per calendar year who received guideline care during pre-and postparity and the logistic regression results. Both before and after parity, at least 90% of the MDD-diagnosed enrollees received some MDD treatment with an antidepressant and/or psychotherapy. Also, before and after parity, the proportion receiving any antidepressant was higher than the proportion receiving any psychotherapy (nearly 80% vs. approximately 55%). When each plan was analyzed separately, there was some variability in the proportion receiving each of the quality measures preparity; the proportions were typically similar postparity.
The pooled logistic regression results indicate the likelihood of receiving any antidepressant or psychotherapy increased postparity. This seemed to be driven largely by an increase in the likelihood of receiving an antidepressant. The individual health plan analyses were similar but there were some differences. PPO-MA1 was the only plan to experience a decrease after parity: the likelihood of receiving any psy-chotherapy declined (odds ratio ͓OR͔, 0.87; confidence interval ͓CI͔, 0.81-0.94). However, postparity, they were more likely to receive antidepressant medication and either treatment modality (OR, 1.14; CI, 1.03-1.26 and OR, 1.23; CI, 1.09 -1.39, respectively). Notably, before parity, PPO-MA1 had the highest proportion receiving any psychotherapy across plans (approximately 64%); after parity, it had declined to approximately 61% but was still among the highest of the plans. Table 4 describes the unadjusted frequencies of receiving the acute-phase quality measures as well as the results of the logistic regressions for these measures. The proportion of acute-phase episodes that received these more nuanced quality standards was overall considerably lower than that seen in the person-year analyses.
In both the pooled and individual plan analyses, there were no statistically significant decreases associated with the postparity period. However, the regression results from the pooled data indicate that the only change was an improvement in the follow-up duration. In the individual plan-level models, there was modest improvement in the intensity of follow up for PPO-W (intensity of follow up in the first 2 months OR, 1.44; CI, 1.04 -2.00) and PPO-S (intensity of follow up in the second 2 months OR, 1.49; CI, 1.03-2.15). Otherwise, no significant changes postparity were noted at the individual plan level. 
DISCUSSION
These data present a mixed picture in terms of quality improvement postparity.
Both before and after parity, most MDD diagnosed enrollees (at least 90%) received some psychotherapy or antidepressant medication in a given year. Additionally, after parity, all of these PPO plans experienced improvement in some quality indicators, most notably in the likelihood of receiving any antidepressant in a given calendar year. Also, there was an improvement in the duration of follow up during acute-phase treatment. PPO-W and PPO-S experienced some improvement in the intensity of MDD follow up postparity; however, the lower bound of the confidence intervals suggests that although statistically significant, it is of little clinical or policy significance.
Despite these improvements, there was evidence of quality concerns as well, particularly when one goes beyond the minimal standards of quality in the calendar year analyses. Even after parity, only less than 60% of the acute-phase episodes received adequate follow-up duration. Also, the intensity of follow up only met the quality standards approximately 30% of the time. For acute phases with psychotherapy or antidepressant treatment, less than 60% met the minimum duration standard, and approximately 30% met the psychotherapy minimum intensity standard. With the exception of follow-up duration, the likelihood of receiving most of the acute-phase quality measures was largely unchanged postparity. These data show some consistency to similar measures collected by the National Committee on Quality Assurance (NCQA) in private insurance health plans. 37, 38 In years 1999, 2001, and 2002, NCQA observed 3 months continuous antidepressant prescribing rates during acute-phase depression of 58.8%, 56.9%, and 59.8%, respectively, which is similar to our acute-phase observations. Also, the rates for receiving 3 follow-up visits in the first 12 weeks after a depression diagnosis were 21.4%, 19.8%, and 19.2%, respectively, which is lower than our observations for follow-up intensity.
Our results are also consistent with those of Bao and Sturm who found that state parity was not associated with improvements in the perception of improved access or quality for mental health care. 39 However, their data are very different than ours. They used data from surveys in which persons were asked their views on the extent of coverage and quality of health care, broadly defined. Our results are based on claims-based quality measures and therefore measure actual utilization.
There are some important limitations to these data. First, these analyses are based on PPO plans from one large national insurer with multiple regional plans and therefore the results may not be generalizable to other plans or geographic regions in which parity is implemented. Because we limit the analyses to enrollees continuously enrolled all 4 years, we cannot comment on the association between parity implementation and quality for enrollees who were enrolled a shorter period of time.
These data use an algorithm based on administrative data to establish a major depression cohort. The gold standard for establishing a diagnostic cohort is based on structured clinical interviews. Studies examining the agreement between administrative data and either structured clinical interview or chart review have found fair agreement for depressive disorders (Geiger-Brown J, Steinwachs D, Fahey M, et al., personal communication, July 17, 2002) . 40 However, we use a more stringent algorithm than other published claims data studies of MDD quality of care. This approach also likely increases the "false-negative" rate in our cohort identification.
In this stable cohort of enrollees, parity was not associated with improvements in MDD detection rates. The annual treatment analyses indicate there was some improvement in access to any recommended treatments once MDD was identified; however, the marginal improvement was small (90% vs. 92%). Additionally, it was a very minimal quality standard (ie, at least 1 prescription filled, at least 1 psychotherapy visit). The more nuanced measures in the acute-phase analyses that specify minimum frequencies/intensities and durations of follow up tell a modest quality improvement story.
Additionally, it is important to note that some quality improvements in the postparity implementation period varied by plan and by specific measures. This is possibly a result of local contextual differences such as baseline quality in the plans and geographic practice variation (or geographic en-rollee preferences). In other analyses on the FEHBP parity, plans reported they did not change their management strategies postparity. 28 Finally, these analyses do not control for secular trends that would affect quality independent of parity. For example, recent literature indicates that the rate of MDD treatment has increased overall and the rate of antidepressant utilization has increased in particular over the past several years (although at times, MH/SA ambulatory visits in general have remained constant 41 but psychotherapy utilization specifically has declined). [42] [43] [44] [45] [46] In our analyses, the strongest improvements were seen in the likelihood of receiving any guidelinerecommended treatments (ie, either psychotherapy or antidepressants), although these gains typically resulted from increases in the likelihood of receiving antidepressants. Thus, the strongest improvements observed may be entirely related to secular trends and not parity. Difference-in-differences analyses can adjust for secular trends; such analyses performed by coinvestigators of the FEHBP parity implementation study demonstrate that increases observed in the probability of any overall MH/SA use and spending were similar to trends observed in non-FEHBP privately insured populations that served as a study comparison. 28 Thus, it is quite possible that these MDD quality results also reflect secular trends independent of parity implementation.
These results have mixed implications for parity and its effect on quality of mental health care. On the positive side, parity implementation and reliance on mental health carveouts to manage the benefits did not result in quality decrements for the treatment of MDD. However, parity implementation was associated with little consistent or significant improvements in MDD treatment quality. (The exception was the duration of MH/SA follow-up duration once acute-phase MDD was identified.) Many of the improvements seen were consistent with prior literature on secular trends, thus suggesting that the forces shaping the secular trends overpower whatever increases in utilization one might see as a result of parity.
It is notable that both before and after parity implementation, there were considerable shortfalls in MDD quality of care. Although mental health and substance abuse parity is an important goal, it is also clearly not enough if the aim is to improve quality. First, there are many mental health services that do not have comparable services in general medical care (eg, day hospital or residential care) and many private insurance plans do not cover these effective components of care. 12 Second, the literature on quality improvement demonstrates that quality improvement typically involves concerted efforts and interventions that rely on multiple methods/efforts to effect practice change aimed at improving treatment quality 47 ; and the more complex the goals are for practice change, the more effort is required on the part of the organization. 48, 49 Thus, although parity is an important policy goal, it alone is inadequate if one's aim is to improve quality of care.
